140 related articles for article (PubMed ID: 37875043)
1. Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis.
He Y; Wang X
Comput Biol Med; 2023 Dec; 167():107591. PubMed ID: 37875043
[TBL] [Abstract][Full Text] [Related]
2. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Li M; Gao X; Wang X
Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
[TBL] [Abstract][Full Text] [Related]
3. Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response.
Li S; Zhao J; Wang G; Yao Q; Leng Z; Liu Q; Jiang J; Wang W
Arch Dermatol Res; 2024 May; 316(6):262. PubMed ID: 38795156
[TBL] [Abstract][Full Text] [Related]
4. Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
Lin J; Lin Y; Huang Z; Li X
Comput Math Methods Med; 2020; 2020():8836493. PubMed ID: 33273963
[TBL] [Abstract][Full Text] [Related]
5. RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.
Jiang Y; Hu X; Wang Z; Zhang Q; Chen D; Zhao P
Invest New Drugs; 2024 Feb; 42(1):60-69. PubMed ID: 38071684
[TBL] [Abstract][Full Text] [Related]
6. RNA M6A modification shaping cutaneous melanoma tumor microenvironment and predicting immunotherapy response.
Wu Y; He H; Zheng K; Qin Z; Cai N; Zuo S; Zhu X
Pigment Cell Melanoma Res; 2024 Jul; 37(4):496-509. PubMed ID: 38624045
[TBL] [Abstract][Full Text] [Related]
7. A deep learning approach based on multi-omics data integration to construct a risk stratification prediction model for skin cutaneous melanoma.
Li W; Huang Q; Peng Y; Pan S; Hu M; Wang P; He Y
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15923-15938. PubMed ID: 37673824
[TBL] [Abstract][Full Text] [Related]
8. Development of a biomarker signature associated with anoikis to predict prognosis and immunotherapy response in melanoma.
Wu Z; Zhang R; Bao J; Yin M; Wang X
Arch Dermatol Res; 2024 May; 316(6):219. PubMed ID: 38787413
[TBL] [Abstract][Full Text] [Related]
9. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
[TBL] [Abstract][Full Text] [Related]
10. Integrative lactylation and tumor microenvironment signature as prognostic and therapeutic biomarkers in skin cutaneous melanoma.
Zhu Y; Song B; Yang Z; Peng Y; Cui Z; Chen L; Song B
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17897-17919. PubMed ID: 37955686
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
13. Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma.
Liu Q; Nie R; Li M; Li L; Zhou H; Lu H; Wang X
Comput Struct Biotechnol J; 2021; 19():4472-4485. PubMed ID: 34471493
[TBL] [Abstract][Full Text] [Related]
14. Melanoma Molecular Subtypes and Development of Prognostic and Immunotherapy-Related Genetic Characteristics by Ferroptosis Gene Analysis.
Xu L; Zhang Y; Liu T; Wang L; Zhao Z; Zhang X; Li X; Wu W; Yu S
Comput Math Methods Med; 2022; 2022():2992939. PubMed ID: 35516454
[TBL] [Abstract][Full Text] [Related]
15. Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis.
He Y; Wang X
Ann Transl Med; 2020 Sep; 8(17):1050. PubMed ID: 33145269
[TBL] [Abstract][Full Text] [Related]
16. Machine learning-derived immunosenescence index for predicting outcome and drug sensitivity in patients with skin cutaneous melanoma.
Zhu L; Zhang L; Qi J; Ye Z; Nie G; Leng S
Genes Immun; 2024 Jun; 25(3):219-231. PubMed ID: 38811681
[TBL] [Abstract][Full Text] [Related]
17. Analysis on tumor immune microenvironment and construction of a prognosis model for immune-related skin cutaneous melanoma.
Wu M; Wang Z; Zhang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 May; 48(5):671-681. PubMed ID: 37539569
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the tumor-suppressive role of PSMB9 in melanoma through multi-omics and single-cell transcriptome analyses.
Hu X; Hu Z; Zhang H; Zhang N; Feng H; Jia X; Zhang C; Cheng Q
Cancer Lett; 2024 Jan; 581():216466. PubMed ID: 37944578
[TBL] [Abstract][Full Text] [Related]
19. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer.
Yu Y; Zhang W; Li A; Chen Y; Ou Q; He Z; Zhang Y; Liu R; Yao H; Song E
JAMA Netw Open; 2020 Apr; 3(4):e202149. PubMed ID: 32259264
[TBL] [Abstract][Full Text] [Related]
20. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
